Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.

doi:10.1097/COC.0000000000000786

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.

American journal of clinical oncology - 1 Feb 2021

van Breeschoten Jesper, Wouters Michel W J M, de Wreede Liesbeth C, Hilarius Doranne H, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan-Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Suijkerbuijk Karijn P M, Blokx Willeke A M, Ten Tije Albert J, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers Marye J, van den Eertwegh Alfons J M

Abstract excerpt

OBJECTIVE: The aim of this study was to evaluate treatment patterns and overall survival (OS) of patients with BRAFV600 wild-type and BRAFV600-mutant advanced melanoma in the Netherlands. METHODS: We selected patients of 18 years and over, diagnosed between 2016 and 2017 with unresectable stage IIIC or IV melanoma, registered in the Dutch Melanoma Treatment Registry. To assess the association of BRAFV600-mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Kaplan-Meier Estimate

Share to Longitudinal Studies

Share to Melanoma

Share to Netherlands

Share to Proportional Hazards Models

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 33332931
DOI: 10.1097/COC.0000000000000786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.PMID 33332931Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.Semantic proximity Read ↗

The Impact of BRAF Mutational Status on Survival in Melanoma Patients: Single Centre Experience.Semantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.Semantic proximity Read ↗

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.Semantic proximity Read ↗

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.Semantic proximity Read ↗

Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II-III Malignant Melanoma.Semantic proximity Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaSemantic proximity Read ↗

BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.